Response of Neoadjuvant Chemotherapy in Triple Negative Breast Cancer and the Impact of Pathologic Complete Response on Survival, an Institutional Research
DOI:
https://doi.org/10.51253/pafmj.v74i3.4813Keywords:
Disease free survival (DFS), Overall survival (os), Pathologic complete response (PCR), Triple negative breast cancer (TNBC)Abstract
Objective: To evaluate response of neoadjuvant chemotherapy in Stage I-III triple-negative breast cancer and impact of pathologic complete response on survival.
Study Design: Retrospective longitudinal study.
Place and Duration of Study: Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore Pakistan, from Jan 2006 to Jul 2014.
Methodology: All patients with triple-negative breast cancer who received neoadjuvant chemotherapy were included and data was retrieved from cancer registry of hospital. The patients received neoadjuvant chemotherapy followed by surgery. Radiotherapy was given wherever clinically indicated. Kaplan-Meier and log-rank test was used to calculate survival.
Results: Out of 1113 triple negative breast cancer patients, 150 received neoadjuvant chemotherapy. Mean age was 43±7 years. Fifty-two patients (34.7%) achieved pathological complete response (complete eradication of invasive or in situ carcinoma in breast and axilla (ypT0/is/ypN0) in surgical specimen). Over a median follow up of 61 months, 52 patients (34.7%) had disease progression. Patients with pathological complete response had significantly better 5-years disease-free survival (p-value 0.001) and 5-years overall survival (p-value 0.002) in comparison to non-pathological complete response group. The 5-years disease-free survival was 90% in pathological complete response group compared to 55% in non-pathological complete response group. Similarly, 5-years overall survival was 94% in pathological complete response group compared to 70% non-pathological complete response group.
Conclusions: Neoadjuvant chemotherapy is an effective treatment modality in management of triple-negative breast cancer. Achievement of pathological complete response is a potential surrogate endpoint as it is associated with significantly better disease-free survival and overall survival.
Downloads
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
https://doi.org/10.3322/caac.21492
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018; 379(22): 2108-2121. https://doi.org/10.1056/NEJMoa1809615
Siddharth S, Sharma D. Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancers 2018; 10(12): 514.
https://doi.org/10.3390/cancers10120514
Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016; 293(2): 247-269.
https://doi.org/10.1007/s00404-015-3859-y
Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book 2016; 36: 34-42.
https://doi.org/10.1200/EDBK_159135
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26(8): 1275-1281. https://doi.org/10.1200/JCO.2007.14.4147
Andreopoulou E, Kelly CM, McDaid HM. Therapeutic advances and new directions for triple-negative breast cancer. Breast Care 2017; 12(1): 20-27. https://doi.org/10.1159/000455821
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384(9938): 164-172.
https://doi.org/10.1016/S0140-6736(13)62422-8
Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30(15): 1796-1804.
https://doi.org/10.1200/JCO.2011.38.8595
Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol 2017; 35(10): 1049-1060. https://doi.org/10.1200/JCO.2015.63.1010
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13(8): 2329-2334. https://doi.org/10.1158/1078-0432.CCR-06-1109
Zeichner SB, Terawaki H, Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer 2016; 10: 25-36. https://doi.org/10.4137/BCBCR.S32783
Network CGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490(7418): 61-70. https://doi.org/10.1038/nature11412
Marotti JD, de Abreu FB, Wells WA, Tsongalis GJ. Triple-negative breast cancer: next-generation sequencing for target identification. Am J Pathol 2017; 187(10): 2133-2138. https://doi.org/10.1016/j.ajpath.2017.05.018
Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015; 21(7): 1688-1698. https://doi.org/10.1158/1078-0432.CCR-14-0432
Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 2008; 26(5): 778-785. https://doi.org/10.1200/JCO.2007.15.0235
Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97(3): 188-194. https://doi.org/10.1093/jnci/dji021
Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006; 24(13): 2019-2027. https://doi.org/10.1200/JCO.2005.04.1665
Colleoni M, Goldhirsch A. Neoadjuvant chemotherapy for breast cancer: any progress? Lancet Oncol 2014; 15(2): 131-132. https://doi.org/10.1016/S1470-2045(13)70584-9
Thompson A, Moulder-Thompson S. Neoadjuvant treatment of breast cancer. Ann Oncol 2012; 23(suppl 10): x231-236. https://doi.org/10.1093/annonc/mds324
Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, et al. Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response. Ann Surg Oncol 2012; 19(1): 253-258. https://doi.org/10.1245/s10434-011-1877-y
Von Minckwitz G, Timms K, Untch M, Elkin EP, Fasching PA, Schneeweiss A, et al. Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto. J Clin Oncol 2015; 33(15_suppl): 1004. https://doi.org/10.1186/s12885-018-4925-1
Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016; 22(15): 3764-373. https://doi.org/10.1158/1078-0432.CCR-15-2477
Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014;15(7): 747-756.https://doi.org/10.1016/S1470-2045(14)70160-3
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Muhammad Rashid Hanif, Abdul Wahab, Amna Moeed, Shafquat Ali Khan, Rizwan Masood Sheikh, Neelam Siddiqui
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
